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| INTRODUCTION
Increasing evidence demonstrates the close association between energy metabolism and the differentiation and function of various immune cell subsets. [1] [2] [3] Resting T and B cells primarily rely on oxidative phosphorylation (OXPHOS) of glucose to maintain baseline functions.
Activation signals delivered through antigen or cytokine receptors shift their metabolism to glycolysis, which is a faster (although less efficient)
way of producing ATP and synthesizing nucleotides and proteins necessary for cell proliferation and function. 4, 5 However, this normal sequence of events changes significantly with disease. Chronic inflammatory conditions such as parasitic infections and cancer cause myeloid cells to undergo metabolic reprogramming, preferentially using fatty acids as the source of ATP to support their functions. [6] [7] [8] In murine cancer models, myeloid-derived suppressor cells (MDSC) show an increased fatty acid oxidation (FAO), and the use of pharmacologic FAO inhibitors blocks their immunosuppressive functions and enhances antitumour T cell-mediated immunotherapy. 6, 7 Asthma is a chronic obstructive airway disease that affects over 300 million people world-wide and is increasing in incidence. Patients with allergic asthma display a chronic airway inflammation mediated primarily by type 2 T helper (Th2) cells and characterized by the infiltration of the bronchoalveolar mucosa with inflammatory immune cells including dendritic cells, macrophages, eosinophil, and neutrophils, which ultimately lead to the characteristic airway hyperresponsiveness (AHR). [9] [10] [11] Current treatments primarily rely on mixtures of inhaled corticosteroids and bronchodilators, with some patients benefiting from antibodies against IgE or IL-5. 12, 13 Therefore, novel insights into the underlying mechanisms of asthma may suggest new prevention and/or treatment approaches. As such, our goal was to determine whether inflammatory cells in asthma would undergo metabolic reprogramming as shown in other chronic inflammatory conditions and to determine the potential therapeutic effect of FAO inhibition.
The results showed a significant increase in the expression of key FAO enzymes in murine models of asthma. These enzymes included carnitine palmitoyltransferase 1 (CPT1) and 3-hydroxyacyl-CoA dehydrogenase (HADHA). CPT1, the first and rate-limiting enzyme of the FAO pathway, regulates the entry of long-chain fatty acids into the mitochondria by converting acyl-CoAs to acylcarnitine derivatives.
HADHA, on the other hand, is a trifunctional enzyme that catalyses the final three steps in the FAO cycle. Importantly, FAO inhibition blocked AHR, recruitment of inflammatory immune cells, and production of allergen-specific IgE and asthma-associated cytokines and chemokines. Thus, the data suggest that FAO supports the function of inflammatory cells in asthma, and as such, its inhibition may represent a novel therapeutic strategy.
2 | ME TH ODS
| Murine asthma models
Asthma models were established using OVA or house dust mite (HDM) exposure of male C57BL/6J or Balb/c mice (6-8 weeks old) Sera and organs were then collected 24 hours later ( Figure 1A ). 
| Airway hyperresponsiveness
Airway hyperresponsiveness to inhaled methacholine was measured 24 hours after OVA challenge by recording enhanced pause (Penh)
by whole-body plethysmography (EMKA Systems Falls Church, VA).
In brief, baseline readings were taken and averaged for three minutes after animals were placed in a barometric plethysmographic chamber. Saline or increasing concentrations (12.5-100 mg/mL) of aerosolized methacholine were nebulized. Readings were taken and averaged for three minutes after each nebulization, and Penh repre- Biosciences; 1:500). Protocols were described previously. 7 BAL fluids were subjected to cytospin and stained with Diff-Quik (IMEB). and HADHA is shown in Figure S1 . Given the similar results in both asthma models, we used the OVA model to conduct additional experiments.
| Flow cytometry
To determine which of the inflammatory cells had an increased 
| FAO inhibition blocks AHR and OVA-specific
IgE production
Next, we tested the effect of etomoxir, a specific CPT1 inhibitor, in mice sensitized and challenged with OVA. As shown in Figure was measured 24 hours after treatment. A second dose of etomoxir was given 30 minutes after AHR assay, and lungs, spleens, and peripheral blood were harvested 24 hours later (day 16). Although measuring lung resistance is considered a more reliable way of evaluating the lung function, Penh has been shown to correlate well with invasive measures of AHR. 19 Moreover, our studies consistently showed an increased AHR in allergen-exposed C57BL6 mice compared to control mice. 14, 15, 17 In line with these reports, AHR to methacholine was significantly increased in OVA-sensitized and challenged mice versus controls, while etomoxir-treated mice had a significant reduction in AHR ( Figure 3B ). We also tested the effect of the HADHA inhibitor ranolazine. Similarly, there was a significant, although more moderate, decrease in AHR ( Figure 3C ). We then asked whether these effects were specific to the C57BL/6J mice. Therefore, we repeated the OVA sensitization and challenge and treatment in Balb/c mice. The results confirmed the protective effect of etomoxir and ranolazine in Balb/c mice exposed to OVA ( Figure 3D ).
We next tested whether FAO inhibition changed IgE levels in allergen-exposed mice. High levels of OVA-specific IgE were induced found in BAL and sera of OVA-exposed animals over controls. However, etomoxir treatment significantly reduced the OVAspecific IgE ( Figure 3E ). In addition and consistent with previous reports, 20 total serum IgE and OVA-specific IgE were markedly increased after OVA. Although etomoxir treatment slightly decreased the levels of total serum IgE, this effect did not achieve statistical significance ( Figure 3F ). However, the decrease in OVA-specific IgE in serum and BAL were significant ( Figure 3E ). This reduction in (KC) ( Figure 6B and Figure S4B ). These changes, however, were not the result of a systemic immunosuppressive effect of etomoxir as the levels of other cytokines such as IFN-c, G-CSF, and GM-CSF did not change significantly in BAL fluid or serum ( Figure S5A ,B, respectively).
| Effect of FAO inhibition on lung macrophages
Given the importance of macrophages in allergic airway inflammation 16, 21, 22 HADHA, and PGC1b were increased in macrophages sorted from allergen-exposed lungs, etomoxir treatment reduced these enzymes to normal levels ( Figure 7B ). There were no significant changes in the expression of ACADM ( Figure 7B ). In addition, we tested the mRNA levels for arginase I and NOS2, factors important in the pathophysiology of asthma. As shown in Figure 6C , lung macrophages from allergic mice had significantly higher levels of arginase I and lower levels of NOS2 compared to controls, confirming an M2 phenotype. However, FAO inhibition with etomoxir significantly reduced arginase I and conversely elevated NOS2 expression.
We next sought to test the role of macrophages in the protective effects induced by FAO inhibitors. For this, we used intravenous injection of liposomal clodronate to deplete circulating inflammatory monocytes, presumed progenitors of lung-recruited macrophages that have been shown to play a role in allergic asthma, while resident alveolar macrophages have been found to restrain allergic lung inflammation. 16, 21 Consistent with these reports, our data showed that liposomal clodronate alone decreased the number of total leucocytes, eosinophils, and macrophages in the BAL fluids of OVA-exposed mice ( Figure 7D ). Moreover, liposomal clodronate reduced the production of IL-5 in BAL fluid and serum ( Figure 7E ). 
Control (PBS) liposomes did not have any effects on
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